

Title: Predictors and risk factors of short-term and long-term outcomes among women with gestational diabetes mellitus (GDM) and their offspring: Moving toward precision prognosis?

Authors: Zhila Semnani-Azad¹, Romy Gaillard², Alice E Hughes³, Kristen E. Boyle⁴, Deirdre K. Tobias^{1,5}, Wei Perng⁶, as part of ADA/EASD PMDI

¹ Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

² Department of Pediatrics, Erasmus Medical Center, Rotterdam, Netherlands

³ Faculty of Health and Life Sciences, University of Exeter Medical School, Exeter, United Kingdom

⁴ Department of Pediatrics and the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

⁵ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁶ Department of Epidemiology and the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Correspondence:

Zhila Semnani-Azad, PhD

Department of Nutrition, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115. **T:** (617) 495-1000. **E-mail:** zsemnaniazad@hsph.harvard.edu

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; MetS – metabolic syndrome; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes

Funding:

Zhila Semnani-Azad is funded by Canadian Institutes of Health Research (CIHR) Fellowship.

Romy Gaillard is funded by the Dutch Diabetes Foundation (grant number 2017.81.002), the Netherlands Organization for Health Research and Development (NWO, ZonMw, grant number 543003109; NWO, ZonMw VIDI 09150172110034) and from the European Union's Horizon 2020 research and innovation programme under the ERA-NET Cofund action (no 727565), EndObesity, ZonMW the Netherlands (no. 529051026).

Alice Hughes is funded the Wellcome Trust GW4-Clinical Academic PhD Fellowship [WT203918].

Kristen Boyle is funded by R01DK117168.

Deirdre K. Tobias is funded by ADA-1-19-JDF-115.

Wei Perng is funded by American Diabetes Association (ADA)-7-22-ICTSPM-08 and National Institutes of Health (NIH) U01 DK134981.

Conflict of interest/disclosure statement: The funders played no role in the design, methodology, or interpretation of results of this work.

1 **ABSTRACT**

2 As part of the American Diabetes Association Precision Medicine in Diabetes Initiative
3 (PMDI) – a partnership with the European Association for the Study of Diabetes (EASD) – this
4 systematic review is part of a comprehensive evidence evaluation in support of the 2nd
5 International Consensus Report on Precision Diabetes Medicine. Here, we sought to synthesize
6 evidence from empirical research papers published through September 1st, 2021 to evaluate and
7 identify prognostic conditions, risk factors, and biomarkers among women and children affected
8 by gestational diabetes mellitus (GDM), focusing on clinical endpoints of cardiovascular disease
9 (CVD) and type 2 diabetes (T2D) among women with a history of GDM; and adiposity and
10 cardiometabolic profile among offspring exposed to GDM *in utero*. We identified a total of 107
11 observational studies and 12 randomized controlled trials testing the effect of pharmaceutical
12 and/or lifestyle interventions. Broadly, current literature indicates that greater GDM severity,
13 higher maternal body mass index, belonging to racial/ethnic minority group; and unhealthy
14 lifestyle behaviors would predict a woman’s risk of incident T2D and CVD, and an unfavorable
15 cardiometabolic profile among offspring. However, the level of evidence is low (Level 4
16 according to the Diabetes Canada 2018 Clinical Practice Guidelines for diabetes prognosis)
17 largely because most studies leveraged retrospective data from large registries that are vulnerable
18 to residual confounding and reverse causation bias; and prospective cohort studies that may
19 suffer selection and attrition bias. Moreover, for the offspring outcomes, we identified a
20 relatively small body of literature on prognostic factors indicative of future adiposity and
21 cardiometabolic risk. Future high-quality prospective cohort studies in diverse populations with
22 granular data collection on prognostic factors, clinical and subclinical outcomes, high fidelity of
23 follow-up, and appropriate analytical approaches to deal with structural biases are warranted.

24 1. INTRODUCTION

25 Gestational diabetes mellitus (GDM) is the most common metabolic disorder of
26 pregnancy, affecting 6-12% of pregnancies globally ^{1,2}. A diagnosis of GDM indicates a state of
27 maternal hyperglycemia due to insufficient insulin secretion and/or insulin resistance that is
28 associated not only with risk of acute pregnancy complications, but also carries implications for
29 the long-term health of the mother and offspring. For instance, in women, GDM is associated
30 with up to 70% higher cumulative incidence of type 2 diabetes (T2D) following the index
31 pregnancy ³ and two-fold greater risk of cardiovascular disease (CVD) than gravidas without
32 GDM ⁴. Additionally, offspring exposed to GDM *in utero* have higher adiposity and a worse
33 metabolic profile than their unexposed counterparts ⁵. The wide-ranging and intergenerational
34 sequelae of GDM-affected pregnancies emphasize the importance of characterizing not only the
35 short- and long-term consequences of this common pregnancy complication, but also, early
36 bellwethers of such consequences to facilitate preventive intervention of such comorbidities and
37 complications – a concept known as disease *prognosis*.

38 Recent technological advancements have improved the capacity to comprehensively
39 assess physiology. In turn, these developments facilitated the ability to harness metabolic
40 heterogeneity – the phenomenon of interest to precision medicine ⁶, by which similar exposures
41 and risk factors yield differential health sequelae across individuals. In the context of GDM
42 prognosis, this effort requires the identification of prognostic conditions and biomarkers among
43 women with a history of GDM and/or their children who were exposed to GDM *in utero* that
44 may serve as both causal and non-causal indicators of future health risks.

45 Recognizing the relevance of metabolic heterogeneity in accurate and precise assessment
46 of metabolic disease prediction, diagnosis, treatment, and prognosis, the *Precision Medicine in*

47 *Diabetes Initiative* (PMDI) was established in 2018 by the American Diabetes Association
48 (ADA) in partnership with the European Association for the Study of Diabetes (EASD). The
49 ADA/EASD PMDI includes global thought leaders in precision diabetes medicine who are
50 working to address the burgeoning need for better diabetes prevention and care through precision
51 medicine ⁷. This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a
52 comprehensive evidence evaluation in support of the 2nd International Consensus Report on
53 Precision Diabetes Medicine ¹.

54 Here, we synthesize evidence from empirical research papers published through
55 September 1st, 2021 to evaluate and identify prognostic conditions, risk factors, and biomarkers
56 among women and children affected by GDM pregnancies, focusing on clinical endpoints of
57 CVD and T2D among women with a history of GDM; and adiposity and cardiometabolic profile
58 among offspring exposed to GDM *in utero*.

59 2. METHODS

60 2.1. Systematic review protocol development

61 We developed a systematic review protocol to comprehensively include and evaluate
62 individual research studies reporting on risk factors for long-term clinical outcomes in women
63 with GDM and a range of cardiometabolic health and anthropometric outcomes in GDM-
64 exposed offspring. Our strategy aimed to identify two broad categories of empirical studies: (1)
65 populations of women with a history of prior GDM that investigated additional exposures or risk
66 factors for incident postpartum T2D or CVD; (2) populations comprising offspring exposed to
67 GDM *in utero*. Studies including pregnancies unaffected by GDM were eligible only if results
68 among GDM subgroups were reported.

69 Prognostic factors of interest – hereafter also referred to as “exposures” – included
70 sociodemographic and environmental factors, lifestyle and behavioral characteristics, traditional
71 clinical traits, and novel ‘omics biomarkers. We considered these prognostic factors during the
72 perinatal/postpartum periods and across the lifecourse for both the mothers and offspring.
73 Maternal outcomes of interest were incident T2D or CVD, including study-specific composites
74 of clinical cardiovascular events, non-fatal and fatal myocardial infarction or stroke, and chronic
75 kidney disease (CKD). For offspring, we were interested in outcomes reported 12 weeks of age
76 and older, and limited to anthropometrics, glycemic and cardiometabolic traits or biomarkers,
77 and incident metabolic syndrome (MetS), T2D, or CVD.

78 2.2. Data sources, search strategy, and screening criteria

79 We published our search strategy and systematic review protocol to PROSPERO
80 CRD42021276094⁸. We developed search terms for Medline EMBASE, and Cochrane
81 CENTRAL (**Supplemental Table 1**) for eligible citations published in English language from

82 January 1st, 1990 through September 30th, 2021. References of accepted manuscripts and relevant
83 systematic reviews published within the past 2 years were screened to identify additional
84 citations. We included prospective and retrospective observational studies identifying factors
85 with incident outcomes of interest in women or offspring exposed to GDM. We excluded cross-
86 sectional analyses among populations with prevalent disease outcomes or traits. While studies
87 could include non-GDM exposed pregnancies, those without subgroup findings exclusively
88 among GDM pregnancies were excluded. We also included interventions prospectively
89 comparing effects of a treatment assignment on the outcome. Exclusion criteria comprised
90 studies with outcomes <12 weeks postpartum, maternal studies reporting only intermediate
91 phenotypes, glycemic traits, or cardiometabolic biomarkers, and studies in offspring that only
92 assessed endpoints outside of the cardiometabolic outcomes of interest (e.g., neurodevelopment,
93 allergic disease). Using these, two independent reviewers conducted screening at the title abstract
94 level. For accepted citations, two independent reviewers implemented screening of the full
95 manuscripts. Conflicts at all screening stages were resolved by a third reviewer. All screening
96 was conducted in the Covidence online systematic review tracking platform.

97 **2.3. Data extraction and synthesis of results**

98 We developed and piloted a data extraction template for eligible manuscripts. Data
99 included manuscript information, study level details and design, population enrollment and
100 characteristics, exposure and outcome ascertainment and diagnosis criteria, follow-up time of
101 outcome assessment since index GDM pregnancy and other pertinent details. We indicated the
102 population in which outcomes were assessed (e.g., maternal, offspring, or both), and recorded the
103 exposures that were investigated in four broad categories: (i) social/environmental/genetics

104 factors across the life course; (ii) all factors in perinatal/postpartum window; (iii) long-term
105 maternal exposures; and (iv) long-term offspring exposures.

106 **2.4. Quality assessment (risk of bias) and synthesis**

107 We assessed the quality of each study using the Joanna Briggs Institute's (JBI) critical
108 appraisal tools for cohort studies and randomized controlled trials (RCTs) ⁹. For cohort studies,
109 we assessed quality based on 11 items which evaluated population recruitment, exposure and
110 outcome ascertainment, confounding, statistical methodology, and follow-up. For the RCTs, the
111 JBI criteria evaluated 13 items which assessed selection and allocation, intervention,
112 administration, outcome ascertainment, follow-up, and statistical analysis. Each JBI item was
113 categorized as 'Yes', 'No', 'Unclear' or 'Not applicable' following the described guidelines.
114 Any uncertainty in assessment was further discussed by the full research team.

115 **2.5. Overall evidence certainty assessment and synthesis**

116 The certainty of evidence was determined using the Diabetes Canada 2018 Clinical
117 Practice Guidelines for studies ¹⁰. Levels were based on study design and criteria focused on
118 inception cohort of patients presenting GDM but without outcomes of interest,
119 inclusion/exclusion reproducibility, follow-up of at least 80% of participants, adjustment for
120 confounding factors, and reproducible outcome measures. Scoring ranged from level 1 to 4, with
121 Level 1 indicating the highest certainty of evidence and Level 4 indicating the lowest certainty of
122 evidence. Details on the criteria and guidelines are presented in **Supplemental Table 2**.

123 **3. RESULTS**

124 **Figure 1** displays results of the systematic search and article inclusion process. Of the
125 8,141 studies identified, five were excluded due to duplication. Another 7,770 were excluded
126 following title and abstract review. The remaining 341 studies were reviewed in full. A total of
127 119 studies met the inclusion criteria for this review.

128 **Table 1** outlines the summary of studies included in this systematic review. Of the 119
129 studies identified, 107 were observational studies and 12 were RCTs. Of the observational
130 studies, 57 studies²⁻⁵⁵ reported on maternal outcomes and 51 studies⁵⁶⁻¹⁰⁶ reported on offspring
131 outcomes. Of the RCTs, three evaluated maternal outcomes¹⁰⁷⁻¹⁰⁹ and nine assessed offspring
132 outcomes^{61,91,110-116}. Studies included data from primarily from Caucasian ethnicities with
133 publications mainly from North American (n = 25) and European (n = 39) countries. The sample
134 sizes of the eligible studies ranged from 26 to 23 302.

135

136 **3.1. Maternal outcomes**

137 **3.1.1. Maternal type 2 diabetes**

138 Fifty-one observational studies¹¹⁻⁶¹ (**Table 2**) and three RCTs⁶²⁻⁶⁴ (**Table 3**) assessed
139 socio-demographic, lifestyle, clinical and pregnancy characteristics associated with the risk of
140 T2D among GDM women. The most commonly-studied characteristics were maternal BMI and
141 GDM severity. Twenty-four observational studies showed that a higher BMI, measured prior to
142 pregnancy, pregnancy or during the lifecourse was associated with a higher risk of T2D. Two
143 observational studies further showed that a higher weight gain in the postpartum period also
144 increased the risk of T2D. Fifteen studies assessed the role of GDM severity on the risk of
145 developing T2D and showed that more severe GDM, measured by either clinical markers or need

146 for insulin, was associated with a higher risk of developing T2D (**Table 2**). One study was a
147 RCT; all other studies were observational. Fewer studies explored the role of lifestyle/behavioral,
148 pregnancy, and clinical characteristics. Six studies explored the role of race/ethnicity in risk of
149 T2D, two of which showed no significant associations (**Table 2**). Four studies suggested that the
150 risk was higher among women with non-European ancestry. With regards to pregnancy
151 characteristics, findings were inconsistent with three of six observational studies reporting an
152 association of a complicated pregnancy with higher risk of T2D. The pregnancy complications
153 assessed varied across reports. Six studies explored the role of parity, of which three showed
154 that higher parity was associated with a higher risk of T2D. Four observational studies showed
155 that breastfeeding was associated with reduced risk of developing T2D in later life. Three
156 studies including one RCT focused on various healthy dietary patterns and the risk of T2D
157 among GDM women but showed inconsistent results. Seven small studies used novel clinical
158 biomarkers, including metabolomics, lipidomics, and diabetes auto-antibodies, and found
159 positive associations with T2D.

160 **3.1.2. Maternal cardiovascular diseases**

161 Six observational studies ^{11,31,65-68} (**Table 4**) explored the role of sociodemographic,
162 lifestyle, and pregnancy characteristics in future risk of CVD among women with GDM. Three
163 studies ^{11,66,67} identified maternal BMI, before or during pregnancy, as a determinant of CVD risk,
164 in which overweight and obese women with GDM have a higher risk of future CVD as compared
165 to normal weight women with GDM. A study further showed that a healthy lifestyle – i.e.,
166 healthy diet, physical activity and non-smoking - was associated with a lower risk of CVD
167 among women with GDM ⁶⁶. Two studies showed that pregnancy complications, including

168 gestational hypertension⁶⁸ and stillbirth³¹, predicted risk of CVD among women of GDM. No
169 significant effect modification was found by family history or chronic hypertension.

170 **3.1.3. Quality of studies conducted and certainty of evidence in maternal populations**

171 The quality of studies reviewed herein for prognostic factors indicative of risk of T2D or CVD is
172 low and the overall certainty of evidence ranked between Levels 3 and 4 according to the
173 Diabetes Canada 2018 Clinical Practice Guidelines¹⁰. Most current literature were based on
174 retrospective studies leveraging registry data and observational cohort studies, both of which are
175 vulnerable to bias and an inability to attribute causation to prognostic factors due to residual
176 confounding, reverse causation bias by pre-existing conditions, and other characteristics around
177 time of pregnancy and GDM diagnoses.

178 **3.2. Offspring outcomes**

179 **3.2.1. Anthropometry and body composition**

180 In comparison to the relatively large maternal literature, fewer studies have focused on
181 prognostic factors associated with suboptimal offspring body composition among those exposed
182 to GDM *in utero*. Forty-three observational studies⁵⁶⁻⁹⁸ (**Table 5**) and four RCTs^{110,113,115,116}
183 (**Table 6**) examined associations of sociodemographic, lifestyle, clinical and pregnancy
184 characteristics associated with anthropometric outcomes offspring of GDM women. The most
185 commonly-studied characteristics were maternal BMI, GDM severity, breastfeeding status, and
186 birthweight, and were compared to anthropometric outcomes, specifically BMI and risk of
187 overweight. Five observational studies showed that a higher maternal pre-pregnancy BMI was
188 associated with an adverse body composition in the offspring, reflected by a higher BMI, waist
189 circumference, or body fat mass, and a higher risk of overweight or obesity. Twelve studies
190 assessed the associations of maternal GDM severity, measured by either clinical markers or need

191 for insulin, with offspring body composition. Most of eight observational studies, only three
192 indicated that more severe maternal GDM is associated with a higher offspring BMI and
193 overweight risk. All four identified RCTs evaluated GDM severity and overall showed no
194 significant association with offspring anthropometry or body composition. Four observational
195 studies showed that a higher size at birth is associated with higher BMI and risk of overweight in
196 GDM offspring, but four studies reported no significant associations. Two studies showed that
197 offspring that a higher size at birth but with exposure to breastfeeding were associated with
198 lower offspring BMI and reduced risk of overweight or obesity. With regards to breastfeeding
199 status, only observational studies showed that exclusive breastfeeding and a longer duration of
200 breastfeeding were associated with a lower offspring BMI and lower risk of overweight or
201 obesity. Only four small studies used novel clinical biomarkers, including metabolomics in cord
202 blood and gene expression in muscle and adipose tissue and showed variable associations with
203 body composition. Furthermore, four independent studies using data from the Danish National
204 Birth Cohort indicated that maternal diet consisting of fatty fish ⁷⁷, refined grain ⁹⁸, and sugar-
205 sweetened beverage intake ⁹⁷ were associated with higher offspring BMI, while protein intake
206 did not show significant impact on offspring abdominal fat ⁷⁶.

207 **3.2.2. Cardiometabolic profile**

208 Only a few studies explored risk factors for adverse cardiometabolic outcomes in GDM
209 offspring. These studies focused on blood pressure, lipids, and glycemic markers in the offspring
210 separately or on metabolic syndrome like phenotypes, integrating several of these components
211 and offspring anthropometric measures. Fourteen observational studies ⁶⁹⁻⁸⁷11 (**Table 7**) and
212 seven RCTs ⁸²⁻⁸⁸ (**Table 8**) were identified. Four observational studies assessed associations of
213 different maternal dietary components including macronutrients or specific micronutrients, and

214 showed no consistent associations with offspring cardiometabolic outcomes. Several RCTs
215 compared diet vs insulin treatment of GDM and showed no significant associations with the
216 development of a metabolic syndrome like phenotype in the offspring. One RCT evaluating a
217 lifestyle intervention including exercise and diet counselling for treatment of GDM compared to
218 clinical care showed a higher risk of unfavorable metabolic outcomes in the offspring in the
219 intervention group. One observational study showed that breastfeeding was associated with a
220 lower risk of metabolic syndrome like phenotype in the offspring of GDM women, but one
221 observational study showed no consistent effects. Birthweight was the most commonly-studied
222 predictor of the offspring exposures. Two observational studies showed that a higher birthweight
223 in offspring of GDM women was associated with a higher risk of metabolic syndrome like
224 phenotype in offspring, whereas one study showed no association.

225 **3.2.3. Quality of studies and certainty of evidence conducted in offspring populations**

226 At the individual study level, we identified low quality of evidence for prognostic factors
227 indicative of future adiposity and cardiometabolic risk among offspring exposed to GDM *in*
228 *utero*. As with the maternal literature, most studies focusing on offspring outcomes were based
229 on retrospective study designs leveraging registry data and observational cohort studies, both of
230 which can be fraught with residual confounding and reverse causation bias, as well as structural
231 biases like selection and attrition bias. Moreover, the literature of offspring outcomes remains
232 relatively scant and with potentially inadequate durations of follow-up for manifestation of
233 clinically-relevant cardiometabolic outcomes, though additional research is warranted.
234 Furthermore, the certainty of evidence for maternal and offspring exposures with
235 cardiometabolic outcomes were scored Level 4 based on the Diabetes Canada guidelines,¹⁰

236 based several factors including limited studies, small sample sizes, heterogeneity of study
237 designs, and inadequate statistical methods.

238 **4. DISCUSSION**

239 **4.1. Summary**

240 This systematic review sought to identify prognostic risk factors during the perinatal
241 period and across the lifecourse for maternal and offspring cardiovascular and metabolic
242 outcomes among women and children affected by GDM pregnancies. We hypothesized that
243 worse glycemic control at the time of GDM diagnosis (i.e., severity of GDM), older maternal
244 age, belonging to racial/ethnic minority group; and unfavorable lifestyle behaviors would predict
245 risk of full-blown type 2 diabetes (T2D) and cardiovascular disease (CVD) among women, and
246 an unfavorable cardiometabolic profile among offspring.

247 The studies identified were primarily long-term retrospective and prospective studies.
248 The level of evidence for prognostic risk factors of maternal T2D and CVD and for offspring
249 cardiometabolic risk is low – i.e., Level 4 according to the Diabetes Canada 2018 Clinical
250 Practice Guidelines for diabetes prognosis¹⁰ – largely due to unmeasured confounding by
251 lifestyle behaviors, the possibility of reverse causation bias due to pre-existing chronic
252 conditions prior to or at the time of GDM diagnosis, and for offspring outcomes, the small body
253 of literature on prognostic factors indicative of future adiposity and cardiometabolic risk. In the
254 sections below, we synthesize general findings and comment further on quality of studies.

255 **4.2. Maternal outcomes**

256 **4.2.1. Cardiovascular disease**

257 In line with a large literature demonstrating that women with a history of GDM are at
258 higher risk CVD than their non-diabetic counterparts^{89,90}, studies among women with a history
259 of GDM indicated dose-response associations of GDM severity with these endpoints.
260 Additionally, maternal pre-pregnancy or early pregnancy BMI was the most assessed prognostic

261 factor linked to future CVD risk. Additionally, prenatal smoking, stillbirth, and gestational
262 hypertension were each associated with risk for CVD in women with a history of GDM, whereas
263 chronic hypertension and family history of CVD were not. Given the paucity of available
264 research on CVD risk in women with a history of GDM, and the low certainty of evidence
265 assessment, this is a research area ripe for investigation.

266 **4.2.2. Type 2 diabetes**

267 Among women with GDM, higher BMI at any time in relation to the index pregnancy –
268 i.e., pre-pregnancy, during the index pregnancy including gestational weight gain, and lifecourse
269 measures of weight – predicted higher risk of T2D later in life. GDM severity, typically
270 estimated by use of insulin or higher blood glucose values during the index pregnancy, was
271 consistently associated with higher risk of developing T2D. While few studies assessed race
272 and/or ethnicity as a prognostic risk factor, women of Asian or non-European descent with a
273 history of GDM had higher risk of future T2D than White women^{24,30,50}. Breastfeeding duration
274 and/or exclusivity was consistently associated with lower risk T2D risk following a GDM
275 diagnosis during pregnancy, though follow-up often ended <2 years postpartum – a timeframe
276 within which occult T2D incidence is relatively low. Longer duration follow-up is necessary to
277 better evaluate the benefits of breastfeeding on T2D risk. Other lifestyle factors of interest
278 included physical activity level during the perinatal and postpartum periods, as well as
279 compliance with a healthy diet (e.g., adherence to a Mediterranean or DASH-like dietary pattern;
280 the Healthy Eating Index score). However, observational findings with respect to these variables
281 were mixed and RCTs investigating the effects of dietary interventions yielded mixed results
282^{62,64}.

283 Several studies have examined biomarkers associated with increased risk for T2D
284 following GDM pregnancies, including glycemic control at the time of GDM diagnosis, lipids²⁸,
285 inflammatory biomarkers²⁸, and novel biomarkers lipidomics²³ and metabolomics⁴⁷
286 biomarkers. While these findings align with the literature in other pregnant⁹¹ and non-pregnant
287 populations⁹², the low certainty of evidence from the studies and lack of replication/validation of
288 findings prevent us from drawing firm conclusions regarding which factors may be the best
289 predictors of future diabetes.

290 **4.2.3. Quality of maternal studies**

291 We ranked the quality of evidence for prognostic factors indicative of risk of T2D or
292 CVD in women as Level 4 (low)¹⁰. Most empirical literature comes predominantly from large
293 health care registries that boast large sample sizes and decades of follow-up. However, they carry
294 high risk of bias in terms of identifying and interpretation specific prognostic characteristics as
295 causal risk factors due to residual confounding due to maternal lifestyle, pre-existing chronic
296 conditions, and other characteristics around time of pregnancy and GDM diagnoses. For
297 example, maternal hypertension status in pregnancy as a causal risk factor for T2D or CVD
298 could be explained in part by maternal BMI, diet quality, physical activity, smoking status,
299 socioeconomic factors, and more. In contrast, there are notable large prospective cohorts,
300 including the CARDIA study and the Nurses' Health Study II, which collected detailed
301 prospective information on the above-mentioned variables.

302 **4.3. Offspring outcomes**

303 **4.3.1. Anthropometry and body composition**

304 The most common measure of offspring anthropometry was BMI between 2 and 10 years
305 after birth. In alignment with maternal outcomes, GDM severity and higher maternal pre-

306 pregnancy BMI were associated with higher offspring adiposity, as indicated by
307 overweight/obesity status. Yet, interpretation of these findings should be tempered those of
308 intervention studies showing that GDM treatment did not affect offspring anthropometrics^{82,85,93}.
309 Similarly, RCTs testing the effects of pharmaceutical treatments (Metformin, insulin) and
310 lifestyle interventions⁸³ to prevent GDM^{94,95}. Other frequently studied perinatal predictors of
311 offspring adiposity included birth size and breastfeeding duration/exclusivity. Generally, higher
312 birthweight tended to be positively correlated with offspring BMI, though this association may
313 be explained by the correlation between maternal and offspring BMI⁹⁴. Some observational
314 studies showed a protective effect of breastfeeding on offspring childhood obesity risk, though
315 this finding was not consistent and we did not identify any RCTs to support this finding. While a
316 few studies reported a modifying effect of offspring sex on future body composition (e.g.,⁹⁶⁻⁹⁸),
317 the direction of association was not consistent.

318 **4.3.2. Cardiometabolic profile**

319 Most studies that assessed offspring cardiometabolic profile were observational and
320 focused on prognostic factors that occurred during the perinatal/postpartum period, though we
321 identified a few RCTs that targeted maternal glycemic control during pregnancy via
322 pharmaceutical treatments and/or lifestyle alterations.

323 Among observational studies, the most common prognostic factor was GDM severity
324^{86,99-101} at times assessed in conjunction with maternal BMI¹⁰⁰. Although the magnitude of
325 effects for GDM severity ranged across populations, greater severity was associated with worse
326 glycemic control and an unfavorable cardiovascular profile in offspring. In addition to traditional
327 biomarkers, one study identified hypothalamic activation as a determinant of BMI gain within
328 the next year – a phenomenon that may mediate and/or modify the effect of GDM exposure *in*

329 *utero*¹⁰². As with the studies discussed above with respect to offspring anthropometry and body
330 composition, RCTs to prevent GDM among high-risk women generally found minimal effects of
331 the pharmaceutical and/or lifestyle interventions on offspring cardiometabolic profile, again
332 suggesting that additional research is needed to better understand the pathophysiology of
333 maternal GDM, to characterize relevant *in utero* programming pathways, and perhaps identify
334 more specific and relevant offspring outcomes⁵.

335 **4.3.3. Quality of offspring studies**

336 As with the maternal studies, we categorized the literature on prognostic factors for
337 offspring outcomes as being of low quality (Level 4). The inconsistent observational findings in
338 conjunction with null results of RCTs targeting prevention of GDM among high-risk women
339 indicate the existence of residual confounding for observational studies, and in the cases of the
340 trials, the possibility that the interventions were developed with a suboptimal endpoint.
341 Specifically, many prenatal interventions among women at high risk of GDM were developed
342 with the goal of preventing macrosomia, which is a relatively crude indicator of developmental
343 overnutrition and offspring adiposity. Future work is needed to gain a better understanding of *in*
344 *utero* programming mechanisms that may link maternal GDM to offspring adiposity, as well as
345 *de novo* interventions formulated to prevent neonatal adiposity assessed via gold standard
346 methods such as air displacement plethysmography or dual X-ray absorptiometry⁵.

347 **5. STRENGTHS AND LIMITATIONS**

348 **5.1. Strengths and limitations of studies included in the systematic review**

349 A key strength of many studies included in this systematic review is the prospective study
350 design, which enhances temporal and causal inference regarding prognostic capacity of the
351 maternal and offspring characteristics and behaviors assessed in studies herein. Additional

352 strengths of some, but not all studies, include multi-ethnic study populations, which enhance
353 generalizability of findings; large sample sizes, which improves capacity to detect biologically
354 relevant associations; and use of gold standard assessments of the maternal and offspring
355 outcomes of interest.

356 Limitations include the low-grade quality of studies included in this review (residual
357 confounding, reverse causation bias, attrition and selection bias, inadequate duration of follow-
358 up). Additionally, most studies were not designed to explore the long-term prognosis of GDM.
359 Accordingly, many studies comprise *post hoc* analyses that were likely underpowered to detect
360 smaller but biologically relevant effects of prognostic risk factors solely among mothers and/or
361 offspring exposed to GDM. *Nota bene*, when screening studies, we noted that a general
362 limitation of the literature on GDM prognostics in relation to offspring outcomes is assessment
363 of the prognostic variable(s) contemporaneously with outcome assessment. These shortcomings
364 resulted in high risk of bias and low quality of studies reviewed herein.

365 **5.2. Strengths and limitations of systematic review approach and methodology**

366 Strengths of the methodology for this systematic review include implementation of at
367 least two independent reviews across all phases of the extraction and assessment process, with an
368 additional review by a third independent reviewer to resolve conflicts; and adherence to well-
369 established assessments of research quality and assessments of bias. Limitations include the
370 exclusively qualitative synthesis of results – a necessity given the relatively small number of
371 studies identified; and as with all systematic reviews, the potential for our conclusions to be
372 impacted by publication bias.

373 **6. FUTURE DIRECTIONS**

374 Given the low quality of evidence identified in this systematic review, there is need for
375 prospective cohort studies in diverse populations with granular data collection on prognostic risk
376 factors as well as clinical and subclinical outcomes; high fidelity of follow-up across the
377 lifecourse but, in particular, during sensitive windows of development during which there is
378 greater developmental plasticity to respond to external cues ¹⁰³; consideration of appropriate
379 adjustment covariates depending on the specific prognostic risk factor of interest (e.g., there is
380 discourse regarding whether maternal pre-pregnancy BMI should be included as a covariate in
381 models where GDM severity is the prognostic risk factors of interest given that these two
382 variables likely share overlapping *in utero* programming pathways ^{117,118}); and appropriate causal
383 inference ¹⁰⁴ and analytical approaches ¹⁰⁵ to address structural biases that afflict observational
384 study designs.

385 As interest in the application of precision prognostics to improve health for women and
386 children affected by GDM pregnancies grows, there remains a need to establish a foundational
387 knowledge base regarding traditional prognostic factors which, in turn, will enhance our ability
388 to identify novel prognostic biomarkers that improve risk stratification for unfavorable health
389 outcomes among mother-offspring dyads affected by GDM.

390 **ACKNOWLEDGEMENTS**

391 The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was conducted,
392 has received the following support: The Covidence license was funded by Lund University
393 (Sweden) for which technical support was provided by Maria Björklund and Krister Aronsson
394 (Faculty of Medicine Library, Lund University, Sweden). Administrative support was provided
395 by Lund University (Malmö, Sweden), University of Chicago (IL, USA), and the American
396 Diabetes Association (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup,
397 Denmark) provided grant support for in-person writing group meetings (PI: L Phillipson,
398 University of Chicago, IL). We also thank Marie-France Hivert for her valuable insights and
399 feedback on this work.

400

401 **REFERENCES**

- 402 1. Nolan JJ, Kahkoska AR, Semnani-Azad Z, et al. ADA/EASD Precision Medicine in
403 Diabetes Initiative: An International Perspective and Future Vision for Precision
404 Medicine in Diabetes. *Diabetes care*. 2022;45(2):261-266.
- 405 2. Gunderson EP, Lewis CE, Lin Y, et al. Lactation Duration and Progression to Diabetes in
406 Women Across the Childbearing Years: The 30-Year CARDIA Study. *JAMA internal
407 medicine*. 2018;178(3):328-337.
- 408 3. Vince K, Poljičanin T, Brkić M, Rodin U, Matijević R. Prevalence of diabetes five years
409 after having gestational diabetes during pregnancy - Croatian national study. *Primary
410 care diabetes*. 2018;12(4):325-330.
- 411 4. Varner MW, Rice MM, Landon MB, et al. Pregnancies After the Diagnosis of Mild
412 Gestational Diabetes Mellitus and Risk of Cardiometabolic Disorders. *Obstetrics and
413 gynecology*. 2017;129(2):273-280.
- 414 5. Li W, Leng J, Liu H, et al. Nomograms for incident risk of post-partum type 2 diabetes in
415 Chinese women with prior gestational diabetes mellitus. *Clinical endocrinology*.
416 2019;90(3):417-424.
- 417 6. Liu H, Zhang C, Zhang S, et al. Prepregnancy body mass index and weight change on
418 postpartum diabetes risk among gestational diabetes women. *Obesity (Silver Spring, Md)*.
419 2014;22(6):1560-1567.
- 420 7. Li W, Zhang S, Liu H, et al. Different associations of diabetes with β -cell dysfunction and
421 insulin resistance among obese and nonobese Chinese women with prior gestational
422 diabetes mellitus. *Diabetes care*. 2014;37(9):2533-2539.

- 423 8. Steinhart JR, Sugarman JR, Connell FA. Gestational diabetes is a herald of NIDDM in
424 Navajo women. High rate of abnormal glucose tolerance after GDM. *Diabetes care*.
425 1997;20(6):943-947.
- 426 9. Hakkarainen H, Huopio H, Cederberg H, Voutilainen R, Heinonen S. Delivery of an LGA
427 infant and the maternal risk of diabetes: A prospective cohort study. *Primary care*
428 *diabetes*. 2018;12(4):364-370.
- 429 10. Wang Y, Chen L, Horswell R, et al. Racial differences in the association between
430 gestational diabetes mellitus and risk of type 2 diabetes. *Journal of women's health*
431 (2002). 2012;21(6):628-633.
- 432 11. Chodick G, Elchalal U, Sella T, et al. The risk of overt diabetes mellitus among women
433 with gestational diabetes: a population-based study. *Diabetic medicine : a journal of the*
434 *British Diabetic Association*. 2010;27(7):779-785.
- 435 12. Lappas M, Mundra PA, Wong G, et al. The prediction of type 2 diabetes in women with
436 previous gestational diabetes mellitus using lipidomics. *Diabetologia*. 2015;58(7):1436-
437 1442.
- 438 13. Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus:
439 clinical predictors and long-term risk of developing type 2 diabetes: a retrospective
440 cohort study using survival analysis. *Diabetes care*. 2007;30(4):878-883.
- 441 14. Retnakaran R, Shah BR. Fetal Sex and the Natural History of Maternal Risk of Diabetes
442 During and After Pregnancy. *The Journal of clinical endocrinology and metabolism*.
443 2015;100(7):2574-2580.

- 444 15. Kawasaki M, Arata N, Sakamoto N, et al. Risk factors during the early postpartum period
445 for type 2 diabetes mellitus in women with gestational diabetes. *Endocrine journal*.
446 2020;67(4):427-437.
- 447 16. Lin PC, Hung CH, Huang RD, Chan TF. Predictors of type 2 diabetes among Taiwanese
448 women with prior gestational diabetes mellitus. *Japan journal of nursing science : JJNS*.
449 2016;13(1):3-9.
- 450 17. Rivero K, Portal VL, Vieira M, Behle I. Prevalence of the impaired glucose metabolism
451 and its association with risk factors for coronary artery disease in women with gestational
452 diabetes. *Diabetes research and clinical practice*. 2008;79(3):433-437.
- 453 18. Akinci B, Celtik A, Genc S, et al. Evaluation of postpartum carbohydrate intolerance and
454 cardiovascular risk factors in women with gestational diabetes. *Gynecological
455 endocrinology : the official journal of the International Society of Gynecological
456 Endocrinology*. 2011;27(5):361-367.
- 457 19. Myers JE, Hasan X, Maresh MJ. Post-natal assessment of gestational diabetes: fasting
458 glucose or full glucose tolerance test? *Diabetic medicine : a journal of the British
459 Diabetic Association*. 2014;31(9):1133-1137.
- 460 20. Pintaudi B, Lucisano G, Pellegrini F, et al. The long-term effects of stillbirth on women
461 with and without gestational diabetes: a population-based cohort study. *Diabetologia*.
462 2015;58(1):67-74.
- 463 21. Eades CE, Styles M, Leese GP, Cheyne H, Evans JM. Progression from gestational
464 diabetes to type 2 diabetes in one region of Scotland: an observational follow-up study.
465 *BMC pregnancy and childbirth*. 2015;15:11.

- 466 22. Kugishima Y, Yasuhi I, Yamashita H, et al. Risk factors associated with the development
467 of postpartum diabetes in Japanese women with gestational diabetes. *BMC pregnancy*
468 *and childbirth*. 2018;18(1):19.
- 469 23. Tseng CH. Parental diabetes in Taiwanese diabetic women with and without previous
470 gestational diabetes. *European journal of clinical investigation*. 2008;38(8):555-561.
- 471 24. Bao W, Yeung E, Tobias DK, et al. Long-term risk of type 2 diabetes mellitus in relation
472 to BMI and weight change among women with a history of gestational diabetes mellitus:
473 a prospective cohort study. *Diabetologia*. 2015;58(6):1212-1219.
- 474 25. Pirkola J, Pouta A, Bloigu A, et al. Prepregnancy overweight and gestational diabetes as
475 determinants of subsequent diabetes and hypertension after 20-year follow-up. *The*
476 *Journal of clinical endocrinology and metabolism*. 2010;95(2):772-778.
- 477 26. Ley SH, Chavarro JE, Li M, et al. Lactation Duration and Long-term Risk for Incident
478 Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus. *Diabetes*
479 *care*. 2020;43(4):793-798.
- 480 27. Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D, Zhang C. Healthful dietary
481 patterns and type 2 diabetes mellitus risk among women with a history of gestational
482 diabetes mellitus. *Archives of internal medicine*. 2012;172(20):1566-1572.
- 483 28. Tobias DK, Clish C, Mora S, et al. Dietary Intakes and Circulating Concentrations of
484 Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-
485 Risk Women with a History of Gestational Diabetes Mellitus. *Clinical chemistry*.
486 2018;64(8):1203-1210.

- 487 29. Bao W, Tobias DK, Bowers K, et al. Physical activity and sedentary behaviors associated
488 with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: a
489 prospective cohort study. *JAMA internal medicine*. 2014;174(7):1047-1055.
- 490 30. Bao W, Li S, Chavarro JE, et al. Low Carbohydrate-Diet Scores and Long-term Risk of
491 Type 2 Diabetes Among Women With a History of Gestational Diabetes Mellitus: A
492 Prospective Cohort Study. *Diabetes care*. 2016;39(1):43-49.
- 493 31. Huvinen E, Eriksson JG, Koivusalo SB, et al. Heterogeneity of gestational diabetes
494 (GDM) and long-term risk of diabetes and metabolic syndrome: findings from the
495 RADIEL study follow-up. *Acta diabetologica*. 2018;55(5):493-501.
- 496 32. Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after
497 gestational diabetes: a long-term follow-up in a Danish population. *Diabetes care*.
498 2004;27(5):1194-1199.
- 499 33. Schaefer-Graf UM, Klavehn S, Hartmann R, et al. How do we reduce the number of
500 cases of missed postpartum diabetes in women with recent gestational diabetes mellitus?
501 *Diabetes care*. 2009;32(11):1960-1964.
- 502 34. Linné Y, Barkeling B, Rössner S. Natural course of gestational diabetes mellitus: long
503 term follow up of women in the SPAWN study. *BJOG : an international journal of*
504 *obstetrics and gynaecology*. 2002;109(11):1227-1231.
- 505 35. Gunderson EP, Hurston SR, Ning X, et al. Lactation and Progression to Type 2 Diabetes
506 Mellitus After Gestational Diabetes Mellitus: A Prospective Cohort Study. *Annals of*
507 *internal medicine*. 2015;163(12):889-898.

- 508 36. Lai M, Liu Y, Ronnett GV, et al. Amino acid and lipid metabolism in post-gestational
509 diabetes and progression to type 2 diabetes: A metabolic profiling study. *PLoS medicine*.
510 2020;17(5):e1003112.
- 511 37. Wahlberg J, Ekman B, Nyström L, Hanson U, Persson B, Arnqvist HJ. Gestational
512 diabetes: Glycaemic predictors for fetal macrosomia and maternal risk of future diabetes.
513 *Diabetes research and clinical practice*. 2016;114:99-105.
- 514 38. Löbner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women
515 with gestational diabetes mellitus. *Diabetes*. 2006;55(3):792-797.
- 516 39. Daly B, Toulis KA, Thomas N, et al. Increased risk of ischemic heart disease,
517 hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a
518 target group in general practice for preventive interventions: A population-based cohort
519 study. *PLoS medicine*. 2018;15(1):e1002488.
- 520 40. Tam WH, Ma RC, Yang X, et al. Cardiometabolic risk in Chinese women with prior
521 gestational diabetes: a 15-year follow-up study. *Gynecologic and obstetric investigation*.
522 2012;73(2):168-176.
- 523 41. Fan Y, Li W, Liu H, et al. Effects of obesity and a history of gestational diabetes on the
524 risk of postpartum diabetes and hyperglycemia in Chinese women: Obesity, GDM and
525 diabetes risk. *Diabetes research and clinical practice*. 2019;156:107828.
- 526 42. Shen Y, Leng J, Li W, et al. Lactation intensity and duration to postpartum diabetes and
527 prediabetes risk in women with gestational diabetes. *Diabetes/metabolism research and*
528 *reviews*. 2019;35(3):e3115.

- 529 43. Wang L, Liu H, Zhang S, et al. Obesity index and the risk of diabetes among Chinese
530 women with prior gestational diabetes. *Diabetic medicine : a journal of the British*
531 *Diabetic Association*. 2014;31(11):1368-1377.
- 532 44. Yin P, Shao P, Liu H, et al. C-peptide levels and the risk of diabetes and pre-diabetes
533 among Chinese women with gestational diabetes. *Journal of diabetes and its*
534 *complications*. 2017;31(12):1658-1662.
- 535 45. Yuan X, Liu H, Wang L, et al. Gestational hypertension and chronic hypertension on the
536 risk of diabetes among gestational diabetes women. *Journal of diabetes and its*
537 *complications*. 2016;30(7):1269-1274.
- 538 46. Göbl CS, Bozkurt L, Yarragudi R, et al. Biomarkers of endothelial dysfunction in relation
539 to impaired carbohydrate metabolism following pregnancy with gestational diabetes
540 mellitus. *Cardiovascular diabetology*. 2014;13:138.
- 541 47. Yefet E, Schwartz N, Sliman B, Ishay A, Nachum Z. Good glycemic control of
542 gestational diabetes mellitus is associated with the attenuation of future maternal
543 cardiovascular risk: a retrospective cohort study. *Cardiovascular diabetology*.
544 2019;18(1):75.
- 545 48. Weerasiri T, Riley SF, Sheedy MT, Walstab JE, Wein P. Amniotic fluid insulin values in
546 women with gestational diabetes as a predictor of emerging diabetes mellitus. *The*
547 *Australian & New Zealand journal of obstetrics & gynaecology*. 1993;33(4):358-361.
- 548 49. Hanson U, Persson B, Hartling SG, Binder C. Increased molar proinsulin-to-insulin ratio
549 in women with previous gestational diabetes does not predict later impairment of glucose
550 tolerance. *Diabetes care*. 1996;19(1):17-20.

- 551 50. Pallardo F, Herranz L, Garcia-Ingelmo T, et al. Early postpartum metabolic assessment in
552 women with prior gestational diabetes. *Diabetes care*. 1999;22(7):1053-1058.
- 553 51. Dehmer EW, Phadnis MA, Gunderson EP, et al. Association Between Gestational
554 Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young
555 Adults (CARDIA) Study. *American journal of kidney diseases : the official journal of the*
556 *National Kidney Foundation*. 2018;71(1):112-122.
- 557 52. Tobias DK, Stuart JJ, Li S, et al. Association of History of Gestational Diabetes With
558 Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women.
559 *JAMA internal medicine*. 2017;177(12):1735-1742.
- 560 53. Fadl H, Magnuson A, Östlund I, Montgomery S, Hanson U, Schwarcz E. Gestational
561 diabetes mellitus and later cardiovascular disease: a Swedish population based case-
562 control study. *BJOG : an international journal of obstetrics and gynaecology*.
563 2014;121(12):1530-1536.
- 564 54. Kaul P, Savu A, Nerenberg KA, et al. Impact of gestational diabetes mellitus and high
565 maternal weight on the development of diabetes, hypertension and cardiovascular
566 disease: a population-level analysis. *Diabetic medicine : a journal of the British Diabetic*
567 *Association*. 2015;32(2):164-173.
- 568 55. Pace R, Brazeau AS, Meltzer S, Rahme E, Dasgupta K. Conjoint Associations of
569 Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular
570 Disease in Parents: A Retrospective Cohort Study. *American journal of epidemiology*.
571 2017;186(10):1115-1124.

- 572 56. Aris IM, Soh SE, Tint MT, et al. Associations of infant milk feed type on early postnatal
573 growth of offspring exposed and unexposed to gestational diabetes in utero. *European*
574 *journal of nutrition*. 2017;56(1):55-64.
- 575 57. Boerschmann H, Pflüger M, Henneberger L, Ziegler AG, Hummel S. Prevalence and
576 predictors of overweight and insulin resistance in offspring of mothers with gestational
577 diabetes mellitus. *Diabetes care*. 2010;33(8):1845-1849.
- 578 58. Chen YL, Han LL, Shi XL, et al. Adverse pregnancy outcomes on the risk of overweight
579 offspring: a population-based retrospective study in Xiamen, China. *Scientific reports*.
580 2020;10(1):1549.
- 581 59. Crume TL, Ogden LG, Mayer-Davis EJ, et al. The impact of neonatal breast-feeding on
582 growth trajectories of youth exposed and unexposed to diabetes in utero: the EPOCH
583 Study. *International journal of obesity (2005)*. 2012;36(4):529-534.
- 584 60. Dugas C, Kearney M, Mercier R, et al. Early life nutrition, glycemic and anthropometric
585 profiles of children exposed to gestational diabetes mellitus in utero. *Early human*
586 *development*. 2018;118:37-41.
- 587 61. Egeland GM, Meltzer SJ. Following in mother's footsteps? Mother-daughter risks for
588 insulin resistance and cardiovascular disease 15 years after gestational diabetes. *Diabetic*
589 *medicine : a journal of the British Diabetic Association*. 2010;27(3):257-265.
- 590 62. Faith MS, Hittner JB, Hurston SR, et al. Association of Infant Temperament With
591 Subsequent Obesity in Young Children of Mothers With Gestational Diabetes Mellitus.
592 *JAMA pediatrics*. 2019;173(5):424-433.
- 593 63. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational
594 diabetes, birth weight, and adolescent obesity. *Pediatrics*. 2003;111(3):e221-226.

- 595 64. Gunderson EP, Greenspan LC, Faith MS, Hurston SR, Quesenberry CP, Jr. Breastfeeding
596 and growth during infancy among offspring of mothers with gestational diabetes mellitus:
597 a prospective cohort study. *Pediatric obesity*. 2018;13(8):492-504.
- 598 65. Hammoud NM, de Valk HW, Biesma DH, Visser GH. Intrauterine Adiposity and BMI in
599 4- to 5-Year-Old Offspring from Diabetic Pregnancies. *Neonatology*. 2017;111(2):177-
600 181.
- 601 66. Hammoud NM, Visser GHA, van Rossem L, Biesma DH, Wit JM, de Valk HW. Long-
602 term BMI and growth profiles in offspring of women with gestational diabetes.
603 *Diabetologia*. 2018;61(5):1037-1045.
- 604 67. Huang Y, Zhang W, Go K, et al. Altered growth trajectory in children born to mothers
605 with gestational diabetes mellitus and preeclampsia. *Archives of gynecology and*
606 *obstetrics*. 2020;301(1):151-159.
- 607 68. Hui LL, Li AM, Nelson EAS, Leung GM, Lee SL, Schooling CM. In utero exposure to
608 gestational diabetes and adiposity: does breastfeeding make a difference? *International*
609 *journal of obesity (2005)*. 2018;42(7):1317-1325.
- 610 69. Ijäs H, Vääräsmäki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a
611 randomised study of metformin and insulin in gestational diabetes mellitus: growth and
612 development of the children at the age of 18 months. *BJOG : an international journal of*
613 *obstetrics and gynaecology*. 2015;122(7):994-1000.
- 614 70. Kaul P, Bowker SL, Savu A, Yeung RO, Donovan LE, Ryan EA. Association between
615 maternal diabetes, being large for gestational age and breast-feeding on being overweight
616 or obese in childhood. *Diabetologia*. 2019;62(2):249-258.

- 617 71. Kelstrup L, Hjort L, Houshmand-Oeregaard A, et al. Gene Expression and DNA
618 Methylation of PPARGC1A in Muscle and Adipose Tissue From Adult Offspring of
619 Women With Diabetes in Pregnancy. *Diabetes*. 2016;65(10):2900-2910.
- 620 72. Kubo A, Ferrara A, Windham GC, et al. Maternal hyperglycemia during pregnancy
621 predicts adiposity of the offspring. *Diabetes care*. 2014;37(11):2996-3002.
- 622 73. Landi SN, Radke S, Engel SM, et al. Association of Long-term Child Growth and
623 Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
624 *JAMA pediatrics*. 2019;173(2):160-168.
- 625 74. Leng J, Li W, Zhang S, et al. GDM Women's Pre-Pregnancy Overweight/Obesity and
626 Gestational Weight Gain on Offspring Overweight Status. *PloS one*.
627 2015;10(6):e0129536.
- 628 75. Liang Z, Liu H, Wang L, et al. Maternal Gestational Diabetes Mellitus Modifies the
629 Relationship Between Genetically Determined Body Mass Index During Pregnancy and
630 Childhood Obesity. *Mayo Clinic proceedings*. 2020;95(9):1877-1887.
- 631 76. Maslova E, Hansen S, Grunnet LG, et al. Maternal protein intake in pregnancy and
632 offspring metabolic health at age 9-16 y: results from a Danish cohort of gestational
633 diabetes mellitus pregnancies and controls. *The American journal of clinical nutrition*.
634 2017;106(2):623-636.
- 635 77. Maslova E, Hansen S, Strøm M, et al. Fish Intake in Pregnancy and Offspring Metabolic
636 Parameters at Age 9-16-Does Gestational Diabetes Modify the Risk? *Nutrients*.
637 2018;10(10).
- 638 78. Maslova E, Hansen S, Grunnet LG, et al. Maternal glycemic index and glycemic load in
639 pregnancy and offspring metabolic health in childhood and adolescence-a cohort study of

- 640 68,471 mother-offspring dyads from the Danish National Birth Cohort. *European journal*
641 *of clinical nutrition*. 2019;73(7):1049-1062.
- 642 79. Nouhjah S, Shahbazian H, Latifi SM, Malamiri RA, Ghodrati N. Body mass index
643 growth trajectories from birth through 24 months in Iranian infants of mothers with
644 gestational diabetes mellitus. *Diabetes & metabolic syndrome*. 2019;13(1):408-412.
- 645 80. Pirkola J, Pouta A, Bloigu A, et al. Risks of overweight and abdominal obesity at age 16
646 years associated with prenatal exposures to maternal prepregnancy overweight and
647 gestational diabetes mellitus. *Diabetes care*. 2010;33(5):1115-1121.
- 648 81. Schaefer-Graf UM, Pawliczak J, Passow D, et al. Birth weight and parental BMI predict
649 overweight in children from mothers with gestational diabetes. *Diabetes care*.
650 2005;28(7):1745-1750.
- 651 82. Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and
652 early childhood overweight in children from mothers with gestational diabetes mellitus.
653 *Diabetes care*. 2006;29(5):1105-1107.
- 654 83. Shi X, Wang D, Lin M, et al. MATERNAL GESTATIONAL DIABETES MELLITUS
655 AND OFFSPRING BODY MASS INDEX FROM 1 TO 4 YEARS. *Endocrine practice :
656 official journal of the American College of Endocrinology and the American Association
657 of Clinical Endocrinologists*. 2020;26(6):619-626.
- 658 84. Shearrer GE, Whaley SE, Miller SJ, House BT, Held T, Davis JN. Association of
659 gestational diabetes and breastfeeding on obesity prevalence in predominately Hispanic
660 low-income youth. *Pediatric obesity*. 2015;10(3):165-171.

- 661 85. Shokry E, Marchioro L, Uhl O, et al. Transgenerational cycle of obesity and diabetes:
662 investigating possible metabolic precursors in cord blood from the PREOBE study. *Acta*
663 *diabetologica*. 2019;56(9):1073-1082.
- 664 86. Shub A, Churilov L, Miranda M, Georgiou HM, Lappas M. Postpartum maternal
665 adipokines and infant weight for length at 1 year in women with gestational diabetes. *The*
666 *journal of maternal-fetal & neonatal medicine : the official journal of the European*
667 *Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal*
668 *Societies, the International Society of Perinatal Obstet*. 2019;32(9):1571-1574.
- 669 87. Song Q, Wang L, Liu H, et al. Maternal GDM Status, Genetically Determined Blood
670 Glucose, and Offspring Obesity Risk: An Observational Study. *Obesity (Silver Spring,*
671 *Md)*. 2021;29(1):204-212.
- 672 88. Vandyousefi S, Whaley SE, Widen EM, et al. Association of breastfeeding and early
673 exposure to sugar-sweetened beverages with obesity prevalence in offspring born to
674 mothers with and without gestational diabetes mellitus. *Pediatric obesity*.
675 2019;14(12):e12569.
- 676 89. Vohr BR, McGarvey ST. Growth patterns of large-for-gestational-age and appropriate-
677 for-gestational-age infants of gestational diabetic mothers and control mothers at age 1
678 year. *Diabetes care*. 1997;20(7):1066-1072.
- 679 90. Vohr BR, McGarvey ST, Tucker R. Effects of maternal gestational diabetes on offspring
680 adiposity at 4-7 years of age. *Diabetes care*. 1999;22(8):1284-1291.
- 681 91. Wroblewska-Seniuk K, Wender-Ozegowska E, Szczapa J. Long-term effects of diabetes
682 during pregnancy on the offspring. *Pediatric diabetes*. 2009;10(7):432-440.

- 683 92. Zhang S, Liu H, Zhang C, et al. Maternal glucose during pregnancy and after delivery in
684 women with gestational diabetes mellitus on overweight status of their children. *BioMed*
685 *research international*. 2015;2015:543038.
- 686 93. Zhang S, Wang L, Leng J, et al. Hypertensive disorders of pregnancy in women with
687 gestational diabetes mellitus on overweight status of their children. *Journal of human*
688 *hypertension*. 2017;31(11):731-736.
- 689 94. Zhang T, Wang P, Liu H, et al. Physical Activity, TV Watching Time, Sleeping, and Risk
690 of Obesity and Hyperglycemia in the Offspring of Mothers with Gestational Diabetes
691 Mellitus. *Scientific reports*. 2017;7:41115.
- 692 95. Zhao YL, Ma RM, Lao TT, et al. Maternal gestational diabetes mellitus and overweight
693 and obesity in offspring: a study in Chinese children. *Journal of developmental origins of*
694 *health and disease*. 2015;6(6):479-484.
- 695 96. Zhu Y, Olsen SF, Mendola P, et al. Growth and obesity through the first 7 y of life in
696 association with levels of maternal glycemia during pregnancy: a prospective cohort
697 study. *The American journal of clinical nutrition*. 2016;103(3):794-800.
- 698 97. Zhu Y, Olsen SF, Mendola P, et al. Maternal consumption of artificially sweetened
699 beverages during pregnancy, and offspring growth through 7 years of age: a prospective
700 cohort study. *International journal of epidemiology*. 2017;46(5):1499-1508.
- 701 98. Zhu Y, Olsen SF, Mendola P, et al. Maternal dietary intakes of refined grains during
702 pregnancy and growth through the first 7 y of life among children born to women with
703 gestational diabetes. *The American journal of clinical nutrition*. 2017;106(1):96-104.

- 704 99. Kampmann FB, Thuesen ACB, Hjort L, et al. Exposure to Gestational Diabetes Is a
705 Stronger Predictor of Dysmetabolic Traits in Children Than Size at Birth. *The Journal of*
706 *clinical endocrinology and metabolism*. 2019;104(5):1766-1776.
- 707 100. Kampmann FB, Thuesen ACB, Hjort L, et al. Increased leptin, decreased adiponectin and
708 FGF21 concentrations in adolescent offspring of women with gestational diabetes.
709 *European journal of endocrinology*. 2019;181(6):691-700.
- 710 101. Vandyousefi S, Goran MI, Gunderson EP, et al. Association of breastfeeding and
711 gestational diabetes mellitus with the prevalence of prediabetes and the metabolic
712 syndrome in offspring of Hispanic mothers. *Pediatric obesity*. 2019;14(7):e12515.
- 713 102. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association
714 with birth weight, maternal obesity, and gestational diabetes mellitus. *Pediatrics*.
715 2005;115(3):e290-296.
- 716 103. Borgoño CA, Hamilton JK, Ye C, et al. Determinants of insulin resistance in infants at
717 age 1 year: impact of gestational diabetes mellitus. *Diabetes care*. 2012;35(8):1795-1797.
- 718 104. Del Gobbo LC, Song Y, Elin RJ, Meltzer SJ, Egeland GM. Gestational glucose
719 intolerance modifies the association between magnesium and glycemic variables in
720 mothers and daughters 15 years post-partum. *Magnesium research*. 2012;25(2):54-63.
- 721 105. Wilk M, Horodnicka-Józwa A, Moleda P, et al. Assessment of selected carbohydrate
722 parameters in children exposed to gestational diabetes in utero. *Neuro endocrinology*
723 *letters*. 2015;36(5):504-510.
- 724 106. Dugas C, Bélanger M, Perron J, et al. Is A Healthy Diet Associated with Lower
725 Anthropometric and Glycemic Alterations in Predisposed Children Born from Mothers
726 with Gestational Diabetes Mellitus? *Nutrients*. 2019;11(3).

- 727 107. Casey BM, Rice MM, Landon MB, et al. Effect of Treatment of Mild Gestational
728 Diabetes on Long-Term Maternal Outcomes. *American journal of perinatology*.
729 2020;37(5):475-482.
- 730 108. Huang F, Zhang S, Tian Y, et al. Effect of mobile health based peripartum management of
731 gestational diabetes mellitus on postpartum diabetes: A randomized controlled trial.
732 *Diabetes research and clinical practice*. 2021;175:108775.
- 733 109. Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a
734 history of gestational diabetes: effects of metformin and lifestyle interventions. *The*
735 *Journal of clinical endocrinology and metabolism*. 2008;93(12):4774-4779.
- 736 110. Landon MB, Rice MM, Varner MW, et al. Mild gestational diabetes mellitus and long-
737 term child health. *Diabetes care*. 2015;38(3):445-452.
- 738 111. Grotenfelt NE, Wasenius N, Eriksson JG, et al. Effect of maternal lifestyle intervention
739 on metabolic health and adiposity of offspring: Findings from the Finnish Gestational
740 Diabetes Prevention Study (RADIEL). *Diabetes & metabolism*. 2020;46(1):46-53.
- 741 112. Keely EJ, Malcolm JC, Hadjiyannakis S, Gaboury I, Lough G, Lawson ML. Prevalence
742 of metabolic markers of insulin resistance in offspring of gestational diabetes
743 pregnancies. *Pediatric diabetes*. 2008;9(1):53-59.
- 744 113. Malcolm JC, Lawson ML, Gaboury I, Lough G, Keely E. Glucose tolerance of offspring
745 of mother with gestational diabetes mellitus in a low-risk population. *Diabetic medicine :*
746 *a journal of the British Diabetic Association*. 2006;23(5):565-570.
- 747 114. Battin MR, Obolonkin V, Rush E, Hague W, Coat S, Rowan J. Blood pressure
748 measurement at two years in offspring of women randomized to a trial of metformin for
749 GDM: follow up data from the MiG trial. *BMC pediatrics*. 2015;15:54.

- 750 115. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in
751 gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years
752 of age. *Diabetes care*. 2011;34(10):2279-2284.
- 753 116. Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS, Crowther CA. Effect of
754 treatment of gestational diabetes mellitus on obesity in the next generation. *Diabetes*
755 *care*. 2010;33(5):964-968.
- 756 117. Francis EC, Kechris K, Cohen CC, Michelotti G, Dabelea D, Perng W. Metabolomic
757 Profiles in Childhood and Adolescence Are Associated with Fetal Overnutrition.
758 *Metabolites*. 2022;12(3).
- 759 118. Perng W, Oken E, Dabelea D. Developmental overnutrition and obesity and type 2
760 diabetes in offspring. *Diabetologia*. 2019;62(10):1779-1788.
- 761 119. Liu H, Zhang S, Wang L, et al. Fasting and 2-hour plasma glucose, and HbA1c in
762 pregnancy and the postpartum risk of diabetes among Chinese women with gestational
763 diabetes. *Diabetes research and clinical practice*. 2016;112:30-36.
- 764 120. Dornhorst A, Bailey PC, Anyaoku V, Elkeles RS, Johnston DG, Beard RW. Abnormalities
765 of glucose tolerance following gestational diabetes. *The Quarterly journal of medicine*.
766 1990;77(284):1219-1228.
- 767 121. Zhang C, Olsen SF, Hinkle SN, et al. Diabetes & Women's Health (DWH) Study: an
768 observational study of long-term health consequences of gestational diabetes, their
769 determinants and underlying mechanisms in the USA and Denmark. *BMJ open*.
770 2019;9(4):e025517.

- 771 122. Väärasmäki M, Pouta A, Elliot P, et al. Adolescent manifestations of metabolic syndrome
772 among children born to women with gestational diabetes in a general-population birth
773 cohort. *American journal of epidemiology*. 2009;169(10):1209-1215.
774

TABLE 1. Summary of studies included in this systematic review, stratified by maternal, offspring, and maternal and offspring outcomes.

Author Year	Country	Study name or site (Year of birth)	Exposure	Maternal outcome(s) or offspring outcome(s)	Method of GDM ascertainment	Sample Size
MATERNAL OUTCOMES						
Ratner 2008 ¹⁰⁹	USA	RCT, Diabetes Prevention Program (DPP)	Maternal life-course	T2D	Self-report	350
Gillman 2010 ¹¹⁶	Australia	Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS)	Perinatal/postpartum	Anthropometrics	Not specified	199
Ijäs 2015 ⁶⁹	Finland	RCT (NCT01087866), Oulu University Hospital (2005-2007)	Perinatal/postpartum	Anthropometrics	Not specified	93
Huvinen 2018 ³¹	Finland	Finnish Gestational Diabetes Prevention Study (RADIEL)	Perinatal/postpartum	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Biochemical test	Maternal: 179 Offspring: 127
Landon 2015 ¹¹⁰ , Vарner 2017 ⁴	USA	RCT, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network	Perinatal/postpartum	Maternal: T2D; Offspring: T2D; CVD composite; Other: Metabolic syndrome; Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Biochemical test	Maternal: 457 Offspring: 500
Battin 2015 ¹¹⁴ , Rowan 2011 ¹¹⁵	New Zealand	Metformin in Gestational diabetes (MiG): the offspring follow-up (TOFU) ACTRN12605000311651)	Perinatal/postpartum	Anthropometrics; Cardiometabolic biomarkers		
Hanson 1996 ⁴⁹	Sweden	RCT, Karolinska Hospital and St. Goran's Hospital (1981-1984)	Maternal life-course	T2D	Not specified	97
Keely 2008 ¹¹² , Malcolm 2006 ¹¹³	Canada	RCT, Ottawa Hospital Ontario (1991-1995)	Perinatal/postpartum; Offspring life-course	Glycemic traits; Cardiometabolic biomarkers; Metabolomic syndrome; T2D		
Liu 2014 ⁶ , Fan 2019 ⁴¹ , Li 2014 ⁷ , Li 2019 ⁵ , Liu 2016 ¹¹⁹ , Wang 2014 ⁴³	China	Tianjin Gestational Diabetes Mellitus Prevention Program	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D		
Pallardo 1999 ⁵⁰	Spain	University Hospital La Paz, Madrid (1987-1997)	Social/environmental/genetic; Perinatal/postpartum	T2D	Biochemical test	788
Myers 2014 ¹⁹	UK	St. Mary's Hospital, Manchester	Social/environmental/genetic	T2D	Biochemical test	629

		(2003-2013)				
Dornhorst 1990 ¹²⁰	UK	St. Mary's Hospital, London (1976-1982)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	56
Linne 2002 ³⁴	Sweden	Stockholm Pregnancy and Women's Nutrition (SPAWN) study	Perinatal/postpartum; Maternal life-course	T2D	Medical records	28
Vince 2018 ³	Croatia	CroDiab National Registry	Perinatal/postpartum	T2D	Medical records	853
Zhang 2019 ¹²¹ , Ley 2020 ²⁶	Denmark and USA	Diabetes & Women's Health (DWH) Study	Perinatal/postpartum	T2D	Self-report	7759
Akinci 2011 ¹⁸	Turkey	Dokuz Eylul University Hospital, Izmir (2002-2008)	Perinatal/postpartum	T2D	Biochemical test	195
Yefet 2019 ⁴⁷	Israel	Emek Medical Center (1991-2011)	Perinatal/postpartum	T2D	Biochemical test	446
Lobner 2006 ³⁸	Germany	German GDM Prospective Study, Births 1989-1999	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	302
Retnakaran 2015 ¹⁴	Canada	Ontario births 200-2010	Perinatal/postpartum; Offspring life-course	T2D	Medical records	23302
Steinhart 1997 ⁸	USA	Indian Health Service	Perinatal/postpartum	T2D	Medical records	111
Lin 2016 ¹⁶	Taiwan	Kaohsiung Medical University (2011)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	130
Hakkarainen 2018 ⁹	Finland	Kuopio University Hospital, Births 1989-2009	Perinatal/postpartum	T2D	Medical records	444
Wang 2012 ¹⁰	USA	Louisiana State University Hospital	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	1142
Chodick 2010 ¹¹	Israel	Maccabi Healthcare Services (1995-2009)	Perinatal/postpartum	T2D	Medical records; Biochemical test	11270
Lappas 2015 ¹²	Australia	Mercy Hospital for Women, Melbourne (2003-2005)	Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	104
Lee 2007 ¹³	Australia	Mercy Hospital for Women, Melbourne (1971-2003)	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D	Medical records	5,470
Weerasiri 1993 ⁴⁸	Australia	Mercy Hospital for Women, Melbourne (1985-1992)	Perinatal/postpartum	T2D	Biochemical test	216
Schaefer-Graf 2009 ³³	Germany	Multi-Center (2000-2005)	Perinatal/postpartum	T2D	Medical records	605
Kugishima 2018 ²²	Japan	Nagasaki Medical Center (2003-2014)	Social/environmental/genetic; Perinatal/postpartum	T2D	Biochemical test	306
Kawasaki 2020 ¹⁵	Japan	National Center for Child Health and Development Tokyo, Osaka Women's and Children's Hospital, Nagasaki Medical	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	399

Center (1995-2011)						
Tseng 2008 ²³	Taiwan	National Health Insurance Database (NR)	Social/environmental/genetic	T2D	Self-report	510
Eades 2015 ²¹	Scotland	Ninewells Hospital, Dundee (1994-2004)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	164
Rivero 2008 ¹⁷	Brazil	Pe. Jeremias' Hospital	Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	109
Fadl 2014 ⁵³	Sweden	Swedish Medical Birth Register (SMBR)	Perinatal/postpartum; Maternal life-course	T2D; CVD	Biochemical test	15949
Kaul 2015 ⁵⁴	Canada	Alberta Perinatal Health Program	Perinatal/postpartum	T2D; CVD	Medical records	8731
Gunderson 2018 ²	USA	Coronary Artery Risk Development in Young Adults (CARDIA)	Social/environmental/genetic; Maternal life-course; Perinatal/Postpartum	T2D, CKD	Self-report	155
Pintaudi 2015 ²⁰	Italy	National Health System Registry, Puglia (2002-2010)	Perinatal/postpartum	T2D; CVD	Medical records	3851
Bao 2014 ²⁹ , Bao 2015 ²⁴ , Bao 2016 ³⁰ , Tobias 2017 ⁵²	USA	Nurses' Health Study II	Perinatal/postpartum; Maternal life-course; Social/environmental/genetic;	T2D; CVD	Self-report	5292
OFFSPRING OUTCOMES						
Huang 2020 ⁶⁷	USA	Stress in Pregnancy Study (SIPS)	Perinatal/postpartum	Anthropometrics	Medical records	26
Hammoud 2017 ⁶⁵	Netherlands	University Medical Center Utrecht	Perinatal/postpartum	Anthropometrics	Medical records	104
Shearrer 2015 ⁸⁴	USA	Women, Infants and Children Program, Los Angeles County	Perinatal/postpartum; Offspring life-course	Anthropometrics	Self-report	470

Chen 2020 ⁵⁸	China	Xiamen Medical Birth Registry	Social/environmental/genetic; Perinatal/postpartum; Offspring life-course Perinatal/postpartum	Anthropometrics	Medical records	6778
Shub 2019 ⁸⁶	Australia	Mercy Hospital for Women, Melbourne (NR)	Perinatal/postpartum	Anthropometrics	Biochemical test	160
Nouhjah 2019 ⁷⁹	Iran	Ahvazin (2014-2016)	Perinatal/postpartum	Anthropometrics	Biochemical test	438
Kaul 2019 ⁷⁰	Canada	Calgary Region, Births 2005- 2013	Perinatal/postpartum	Anthropometrics	Medical records	5136
Hui 2018 ⁶⁸	China	Children of 1997 Birth Cohort	Perinatal/postpartum	Anthropometrics	Self-report	539
Kubo 2014 ⁷²	USA	Cohort Study of Young Girls' Nutrition, Environment, and Transitions (CYGNET)	Perinatal/postpartum	Anthropometrics	Medical records	27
Schaefer-Graf 2005 ⁸¹ , Schaefer-Graf 2006 ⁸²	Germany	Diabetes Prenatal Care Clinic of the Department of Obstetrics at the Vivantes Medical Center Berlin	Social/environmental/genetic; Perinatal/postpartum; Offspring life-course	Anthropometrics	Medical records; Biochemical test	324
Zhao 2015 ⁹⁵	China	First Affiliated Hospital of Kunming Medical University, Births 2003-2011	Perinatal/postpartum; Offspring life-course	Anthropometrics	Biochemical test	1068
Aris 2017 ⁵⁶	Singapore	Growing Up in Singapore Towards Healthy Outcomes (GUSTO) Study	Perinatal/postpartum; Offspring life-course	Anthropometrics	Biochemical test	181
Gillman 2003 ⁶³	USA	Growing Up Today Study (GUTS) and Nurses' Health Study II	Perinatal/postpartum	Anthropometrics	Self-report	14,881
Landi 2019 ⁷³	New Zealand	National Maternity Collection (MAT)	Perinatal/postpartum; Offspring life-course	Anthropometrics	Medical records	3,928

Crume 2012 ⁵⁹	USA	Exploring Perinatal Outcomes among CHildren (EPOCH)	Social/environmental/genetic Perinatal/postpartum; Offspring life-course	Anthropometrics; Cardiometabolic biomarkers	Medical records	94
Wroblewska-Seniuk 2009 ⁹¹	Poland	Clinical Hospital of Obstetrics and Gynecology, Poznan	Perinatal/postpartum	Anthropometrics; Glycemic traits	Not specified	34
Boerschmann 2010 ⁵⁷	Germany	German GDM Offspring Study, Births 1989-2000	Perinatal/postpartum	Anthropometrics; Glycemic traits	Medical records	232
Shokry 2019 ⁸⁵	Spain	PREOBE Study (NCT01634464; 2008-2012)	Perinatal/postpartum	Anthropometrics; Novel 'omics; Other: The novel 'omics is cord blood metabolomics	Not specified	27
Zhu 2016 ⁹⁶ , Zhu 2017 ⁹⁷ , Zhu 2017 ⁹⁸ , Maslova 2019 ⁷⁸ , Maslova 2018 ⁷⁷ , Maslova 2017 ⁷⁶ , Kampmann 2019 ⁹⁹ , Kampmann 2019 ¹⁰⁰	Denmark	Danish National Birth Cohort (DNBC)	Perinatal/Postpartum; Offspring Life-Course	Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Self-report; Medical records	918
Wilk 2015 ¹⁰⁵	Poland	Pomeranian Medical University, Szczecin (NR)	Offspring life-course	Glycemic traits	Not specified	50
MATERNAL AND OFFSPRING OUTCOMES						
Lauenborg 2004 ³²	Denmark	Rigshospitalet, Denmark (1978-1985, 1987-1996)	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course; Offspring life-course	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Other: GLP-1, GIP, Glucagon; Glycemic traits; Novel 'omics; T2D; Metabolomic syndrome	Not specified	
DelGobbo 2012 ¹⁰⁴	Canada	Royal Victoria Hospital (1989-1991)	Perinatal/postpartum; Maternal life-course	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Not specified	

Vääräsmäki 2009¹²², Pirkola 2010⁸⁰, Pirkola 2010²⁵	Finland	Northern Finland Birth Cohort of 1986	Perinatal/postpartum	Maternal: T2D Offspring: Anthropometrics; Glycemic traits; Cardiometabolic biomarkers; Metabolomic syndrome	Biochemical test	Maternal: 139 Offspring: 95
Gunderson 2015³⁵, Lai 2020³⁶, Faith 2019⁶², Gunderson 2018⁶⁴	USA	Study of Women, Infant Feeding and Type 2 Diabetes after GDM Pregnancy (SWIFT) Study	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	Maternal: T2D Offspring: Anthropometrics	Medical records	Maternal: 959 Offspring: 464

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; GLP – glucagon-like peptide; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes.

TABLE 2. Observational studies evaluating prognostic factors associated with incident T2D among women with a history of GDM (*n*=51).

Author Year	Trial/ Cohort/ Registry	Exposures and associations with incident T2D			
		Perinatal/ Postpartum		Maternal Lifecourse	Social/ Environment/ Genetic
Kaul 2015 ⁵⁴	Alberta Perinatal Health Program & Alberta Ministry of Health	Pre-pregnancy BMI	↑		
Gunderson 2018 ²	Coronary Artery Risk Development in Young Adults (CARDIA)	Breastfeeding	↓		
Vince 2018 ³	CroDiab registry	Pre-pregnancy BMI	↑		Education n.s. Marital Status n.s.
Varner 2017 ⁴	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Parity	↑		
Li 2019 ⁵	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	Pre-pregnancy BMI	↑		Family history of T2D ↑
		Pregnancy Complication	↑		
		GDM severity	↑		
		Age at Pregnancy	n.s.		
Liu 2014 ⁶	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	Pre-pregnancy BMI	↑	Weight Gain ↑	
Liu 2016 ¹¹⁹	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	GDM severity	↑		

Li 2014 ⁷	Follow up of Tianjin Gestational Diabetes Prevention Program		BMI	↑				
Steinhart 1997 ⁸	Indian Health Service	Parity		↑	BMI	↑		
		GDM severity		↑				
		Maternal age		↑				
		Offspring birthweight		↑				
Hakkarainen 2018 ⁹	Kuopio University Hospital	Offspring birthweight		↑				
Wang 2012 ¹⁰	Louisiana State University Hospital-Based Longitudinal Study				Race (African American vs. White)	n.s.		
Chodick 2010 ¹¹	Maccabi Healthcare Services (MHS)	Parity (≥4 vs. 1)		↑	BMI	↑	SES (lowest vs. highest)	↑
		GDM severity		↑	Smoking (current/past vs. never)		n.s.	
Lappas 2015 ¹²	Mercy Health	Novel biomarkers (cholesterol ester species CE 20:4, the alkenylphosphatidylethanolamine species PE(P-36:2) and the phosphatidylserine species PS 38:4)		↑				
Lee 2007 ¹³	Mercy Hospital for Women in Melbourne, Australia	GDM severity		↑			Race (Asian vs. White)	↑
		Offspring birthweight		↑				
Retnakaran 2015 ¹⁴	Ministry of Health and Long-Term Care of Ontario	Offspring sex (Girl vs Boy)		↑				
Kawasaki 2020 ¹⁵	n/a	Pre-pregnancy BMI		↑				
		GDM severity		↑				
Lin 2016 ¹⁶	n/a	Pre-pregnancy BMI		↑				
		GDM severity		↑				
		Offspring birthweight			n.s.			
		Pregnancy complication			n.s.			

Rivero 2008 ¹⁷	N/A	Pre-pregnancy BMI	↑	BMI	↑
				Blood Pressure	↑
				Lipids	↑
				Clinical Markers (CRP)	↑
Akinci 2011 ¹⁸	N/A	GDM severity	↑		
		Pre-pregnancy BMI	n.s.		
Myers 2014 ¹⁹	N/A			Race (Asian vs. White)	↑
Pintaudi 2015 ²⁰	N/A	Pregnancy complication	↑		
Eades 2015 ²¹	N/A	Pregnancy BMI	↑		
		GDM severity	↑		
Kugishima 2018 ²²	National Hospital Organization Nagasaki Medical Center, Omura, Japan	GDM severity	↑		
Tseng 2008 ²³	National Taiwan University College of Medicine			Family history of T2D	n.s.
Bao 2015 ²⁴	NHS II, Diabetes & Women's Health Study	Weight gain	↑	BMI	↑
		Pregnancy BMI	↑		
Pirkola 2010 ²⁵	Northern Finland Birth Cohort of 1986	Pre-pregnancy BMI	↑		
Ley 2020 ²⁶	Nurses' Health Study (NHS) II and Diabetes in Women's Health (DWH) Study	Breastfeeding	↓		
Tobias 2012 ²⁷	Nurse's Health Study II			Diet	↓
Tobias 2018 ²⁸	Nurse's Health Study II			Novel biomarker (Branched chain amino acid)	↑
Bao 2014 ²⁹	Nurses' Health Study II who had a history of GDM, as part of the ongoing Diabetes & Women's Health Study			Physical activity	↓

Bao 2016 ³⁰	Nurses' Health Study II who had a history of GDM, as part of the ongoing Diabetes & Women's Health Study		Diet (high protein/ fat from animal source)	↑	
			Diet (plant protein)	n.s.	
Huvinen 2018 ³¹	RADIEL	Pre-pregnancy BMI	↑		
Lauenborg 2004 ³²	Rigshospitalet Old Cohort, Rigshospitalet New Cohort	Pre-pregnancy BMI	↑		
		GDM severity	↑	Family history of T2D	↑
		Pregnancy complication	n.s.	Race (Nordic vs. non-Nordic)	n.s.
Schaefer-Graf 2009 ³³	N/A	Novel biomarker (risk score: composite of pre-pregnancy BMI, gestational age at diagnosis, and GDM severity)	↑		
Linné 2002 ³⁴	Stockholm Pregnancy and Women's Nutrition (SPAWN) study	Pre-pregnancy BMI	n.s.	BMI	↑
		Parity	n.s.	Clinical Biomarkers	n.s.
Gunderson 2015 ³⁵	SWIFT Cohort	Breastfeeding	↓		
Lai 2020 ³⁶	SWIFT Cohort		Metabolomic profile	↑	
Wahlberg 2016 ³⁷	Swedish Medical Birth Registry (SMBR) in 1902	GDM severity	↑		Race (non-European vs. European)
		Pre-pregnancy BMI	↑		
Lobner 2006 ³⁸	The German GDM Prospective Study	Pre-pregnancy BMI	↑		
		Parity	↑		
		GDM severity	↑		
		Novel biomarker (auto-antibodies to GAD and/or IA2)	↑		
Daly 2018 ³⁹	The Health Improvement Network (THIN) database				Race (Afro-Caribbean and South Asian vs. other)

Tam 2012 ⁴⁰	N/A	Pregnancy BMI	↑	Hypertension	↑
				Clinical markers (lipids and glycemic tests)	n.s.
Fan 2019 ⁴¹	Tianjin GDM Screening Project	Pre-pregnancy BMI	↑		
		Postpartum BMI	↑		
Shen 2019 ⁴²	Tianjin GDM Screening Project	Breastfeeding	↓		
Wang 2014 ⁴³	Tianjin Gestational Diabetes Mellitus Prevention Program			BMI	↑
Yin 2017 ⁴⁴	Tianjin Gestational Diabetes Mellitus Prevention Program			Clinical biomarkers	↑
Yuan 2016 ⁴⁵	Tianjin Gestational Diabetes Mellitus Prevention Program	Pregnancy complications	↑	Chronic hypertension	↑
Gobl 2014 ⁴⁶	Vienna Post-Gestational Diabetes Project			Novel biomarker (sICAM and sE-selectin)	↑
Yefet 2019 ⁴⁷	N/A	GDM severity	↑		
Weerasiri 1993 ⁴⁸	N/A	Novel biomarker (amniotic fluid insulin)	↑		
Hanson 1996 ⁴⁹	N/A			Novel biomarker (Proinsulin:Insulin)	n.s.
Pallardo 1999 ⁵⁰	N/A	Pre-pregnancy BMI	↑		
		GDM severity	↑		
		Parity	n.s.		
		Previous pregnancy complications	n.s.		
		Offspring birthweight	n.s.		

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes.

TABLE 3. Randomized controlled trials (RCT) evaluating prognostic factors associated with incident type 2 diabetes (T2D) among women with a history of GDM ($n=3$).

Author Year	Trial/ Cohort/ Registry	Intervention/exposure and association with T2D	
Casey 2020 ¹⁰⁷	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network's multicenter randomized controlled treatment trial	Diet (formal nutritional counseling and diet therapy with insulin vs. usual prenatal care)	n.s.
Huang 2021 ¹⁰⁸	N/A	GDM severity	↑
		Mobile management	n.s.
Ratner 2008 ¹⁰⁹	Diabetes Prevention Program (DPP)	Intensive lifestyle + Metformin	↑

Abbreviations: GDM – gestational diabetes mellitus; n.s. - not significant

TABLE 4. Observational studies evaluating prognostic factors associated with cardiovascular disease (CVD) among women with a history of GDM ($n=6$).

Author (year)	Trial/ Cohort/ Registry	Exposures and associations with CVD		
		Perinatal/ Postpartum	Maternal Lifecourse	Social/ Environment/ Genetic
Dehmer 2018* ⁵¹	The Coronary Artery Risk Development in Young Adults (CARDIA) Study			Race (Black vs. White) ↑
Tobias 2017 ⁵²	Nurses' Health Study II (NHS II)	Pre-pregnancy BMI ↑	Healthy Lifestyle Score [‡] ↓ Diagnosed with T2D ↑	Family history of CVD n.s.
Fadl 2014 ⁵³	Swedish Medical Birth Register (SMBR)	Pregnancy BMI ↑	Smoking ↑ Chronic hypertension n.s.	
Pintaudi 2015 ²⁰	N/A	Pregnancy complications ↑		
Kaul 2015 ⁵⁴	Alberta Perinatal Health Program & Alberta Ministry of Health		BMI ↑	
Pace 2017 ⁵⁵	N/A	Pregnancy Complications (gestational hypertension) ↑		

Abbreviations: BMI – body mass index; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; n.s. - not significant; T2D – type 2 diabetes.

*Association with chronic kidney disease (CKD) outcome

[‡] Healthy lifestyle score included a combination of diet, BMI, physical activity, and smoking.

TABLE 5. Observational studies evaluating prognostic factors in relation to anthropometric outcomes among offspring exposed to GDM *in utero* (n=43).

Author Year	Trial/Cohort/Registry Name	Age of outcome assessment	Exposure			Association
			Maternal	Offspring	Offspring Outcome	
Aris 2017 ⁵⁶	Growing up today in Singapore (GUSTO) study	24-36 months	Breastfeeding		Weight	n.s.
					BMI	n.s.
Boerschmann 2010 ⁵⁷		11 years			Weight	↑
					Weight	↑
					Birthweight	Weight
Chen 2020 ⁵⁸	Medical Birth Registry of Xiamen	1-5 years		Birthweight	BMI	↑
					Weight	n.s.
Crume 2012 ⁵⁹	Exploring Perinatal outcomes Among CHildren (EPOCH) study	2-13 years	Breastfeeding		BMI	↓
Dugas 2018 ⁶⁰		2-14 years	Breastfeeding		Weight	n.s.

				Waist Circumference	n.s.	
				Fat Mass	n.s.	
				Lean Fat Mass	n.s.	
Egeland 2010 ⁶¹	N/A	15 years	GDM Severity	BMI	n.s.	
				Body fat	n.s.	
Faith 2019 ⁶²	SWIFT Cohort	2-5 years	Breastfeeding	Obesity	↓	
Gillman 2003 ⁶³	Growing Up Today Study and Nurses' Health Study II	9-14 years		Birthweight	Overweight	n.s.
Gunderson 2018 ⁶⁴	SWIFT Offspring Study	12 months	Breastfeeding (vs. Formula)	Weight	↑	
Hammoud 2017 ⁶⁵	University Medical Center Utrecht Women with a pregnancy complicated by type 1, type 2, or gestational diabetes who delivered in the University Medical Center Utrecht, the Netherlands, between 2000 and 2006	4-6 years		Birthweight	BMI	↑
Hammoud 2018 ⁶⁶		1-14 years		Birthweight	BMI	n.s.

Huang 2020 ⁶⁷	SIPS	5 years	Pregnancy Complications		BMI	↑
Hui 2018 ⁶⁸	Children of 1997	16 years	Breastfeeding		Obesity	n.s.
Ijäs 2015 ⁶⁹	Follow-up of RCT of GDM requiring pharmacological treatment at Oulu University Hospital and secondary-level Kainuu Central Hospital	18 months	GDM Severity		Weight	↑
Kaul 2019 ⁷⁰	Calgary Zone	4-6 years	Breastfeeding	LGA	Obesity	↓
			Breastfeeding	Normal Weight	Obesity	n.s.
Kelstrup 2016 ⁷¹	N/A	27-34 years	Gene Expression (Adipose Tissue: PPARGC1A)		Body fat	↓
					BMI	↓
Kubo 2014 ⁷²	Cohort Study of Young Girls' Nutrition, Environment, and Transitions (CYGNET)	10-12 years	Pre-pregnancy BMI		BMI	↑
					Percent Body Fat	↑
					Waist:Hip	↑

Landi 2019 ⁷³	N/A	5 years	GDM Severity	Weight	n.s.
Leng 2015 ⁷⁴	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	Pre-pregnancy BMI & Gestational BMI	BMI	↑
				Weight	↑
Liang 2020 ⁷⁵	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	6 years	BMI Genetic Risk Score	BMI	↑
				Waist Circumference	↑
				Fat Mass	↑
Maslova 2017 ⁷⁶	Danish National Birth Cohort	9-12 years	Diet (Protein Intake)	Abdominal Fat	n.s.
				Total Fat	n.s.
Maslova 2018 ⁷⁷	Danish National Birth Cohort	9-16 years	Diet (fatty fish intake)	BMI	↑
				Waist Circumference	↑
Maslova 2019 ⁷⁸	Danish National Birth Cohort (DNBC)	12 months - 7 years	Pregnancy Diet (Glycemic index and glycemic load)	Fat Mass	n.s.

Nouhjah 2019 ⁷⁹	Ahvazin children born between 2014 and 2016 were enrolled in this study	2 years	Sex (Boy vs Girl)	BMI	n.s.
				Weight	n.s.
Pirkola 2010 ⁸⁰	Northern Finland Birth Cohort of 1986	16 years	Pre-pregnancy BMI	Weight	↑
				Abdominal Fat	↑
Schaefer-Graf 2005 ⁸¹		2-8 years	Pre-pregnancy BMI and GDM severity	BMI	n.s.
				Lifecourse BMI	↑
				Neonatal BMI	↑
				Abdominal circumference	n.s.
Schaefer-Graf 2006 ⁸²		2-8 years	Breastfeeding	Weight	↓
				Breastfeeding + BMI	↓
Shi 2020 ⁸³	Medical Birth Registry of Xiamen	1-4 years	GDM Severity	BMI	n.s.

					Weight	n.s.
Shearrer 2015 ⁸⁴	Women, Infants and Children Program in Los Angeles County	2-4 years	Breastfeeding	BMI		↓
Shokry 2019 ⁸⁵	PREOBE study	1 year	Cord blood biomarkers	BMI		↑
Shub 2019 ⁸⁶		1 year	Leptin and Adiponectin	Weight		n.s.
Song 2021 ⁸⁷	Tianjin Gestational Diabetes Mellitus Prevention Program	6 years	Genetic Risk Score	Weight		n.s.
Vandyousefi 2019 ⁸⁸	2014 Los Angeles County WIC Survey	1-5 years	Breastfeeding	BMI		↓
Vohr 1997 ⁸⁹	N/A	1 year	Birthweight	BMI		↑
				Waist Circumference		↑
				Skinfold		↑
Vohr 1999 ⁹⁰	N/A	4-7 years	Birthweight	BMI		↑
				Waist Circumference		n.s.
				Skinfold		↑
Wroblewska-Seniuk 2009 ⁹¹	N/A	4-9 years	GDM Severity	BMI		n.s.

				Waist Circumference	n.s.	
Zhang 2015 ⁹²	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	GDM Severity	BMI	↑	
Zhang 2017 ⁹³	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	Pregnancy Complications	BMI	↑	
Zhang 2017 ⁹⁴	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	Physical Activity (TV watching)		↑	
Zhao 2015 ⁹⁵		5-10 years	Breastfeeding	Weight	BMI	↓
				Sex (Female)	BMI	↓
				Weight	BMI	n.s.
Zhu 2016 ⁹⁶	Danish National Birth Cohort (DNBC)	7 years	GDM Severity	BMI	↑	
Zhu 2017 ⁹⁷	Danish National Birth Cohort (DNBC)	7 years	Diet (Sugar-sweetened beverage)	BMI	↑	
Zhu 2017 ⁹⁸	Danish National Birth Cohort (DNBC)	7 years	Diet (refined grain)	BMI	↑	

TABLE 6. Randomized control trials evaluating prognostic factors associated with anthropometric outcomes among offspring exposed to GDM *in utero* ($n=4$).

Author Year	Trial Name	Intervention and/or Exposure	Offspring Outcome	Association
Rowan 2011 ¹¹⁵	Metformin in Gestational diabetes (MiG): the offspring follow-up (TOFU)	Treatment (Metformin vs Insulin)	Skinfold	↑
			Waist circumference	n.s.
			Total fat	n.s.
Gillman 2010 ¹¹⁶	Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS)	Treatment (dietary advice, blood glucose monitoring, and insulin therapy) vs. Routine Care	BMI	n.s.
Landon 2015 ¹¹⁰	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Treatment (dietary advice, blood glucose monitoring, and insulin therapy) vs. Routine Care	BMI	n.s.
			Waist circumference	n.s.
Malcolm 2006 ¹¹³	N/A	Tight vs minimal intervention	Weight	n.s.

TABLE 7. Observational studies evaluating prognostic factors in relation to cardiometabolic outcomes among offspring exposed to GDM *in utero* (n=14).

Author Year	Trial/Cohort/Registry Name	Exposure		Offspring Outcome	Association
		Maternal	Offspring		
Maslova 2019 ⁷⁸	Danish National Birth Cohort (DNBC)	Pregnancy Diet (Glycemic index and glycemic load)		HOMA-IR	n.s.
				MetS	n.s.
Maslova 2018 ⁷⁷	Danish National Birth Cohort (DNBC)	Diet (only fish intake)		MetS	n.s.
				Lipids	n.s.
				HOMA-IR	n.s.
Kampmann 2019 ⁹⁹	Danish National Birth Cohort (DNBC)		Birthweight	Fasting glucose	n.s.
				Insulin	n.s.
				C-peptide	n.s.
				HOMA-IR	n.s.

			Lipids	n.s.
Kampmann 2019 ¹⁰⁰	Danish National Birth Cohort	Pre-pregnancy BMI	Leptin	↑
Vandyousefi 2019 ¹⁰¹	SOLAR (Study of Latino Adolescents at Risk for Diabetes)	Breastfeeding and pre-diabetes	MetS	↓
Dugas 2018 ⁶⁰	Institute of Nutrition and Functional Foods, Laval University	Breastfeeding	Fasting glucose	n.s.
			Fasting insulin	n.s.
			HbA1c	↓
			HOMA-IR	n.s.
Zhang 2017 ⁹⁴	Tianjin Gestational Diabetes Mellitus Prevention Program (TGDMPP)	Physical Activity (sedentary behavior)	Hyperglycemia	↑
		Sleeping Time	Hyperglycemia	↓
Boney 2005 ¹⁰²	Women and their children from Women and Infant's hospital	Birthweight (LGA)	MetS	↑
Borgoño 2012 ¹⁰³		Weight Gain (1st year)	HOMA-IR	↑

Del Gobbo 2012 ¹⁰⁴	N/A	Diet (Mg)	Fasting glucose (in females)	↓
Wilk 2015 ¹⁰⁵	N/A	Birthweight	HOMA-IR	↑
Maslova 2017 ⁷⁶	Danish National Birth Cohort (DNBC)	Diet (protein intake)	HOMA-IR	n.s.
			Fasting insulin	↑
Dugas 2019 ¹⁰⁶	Institute of Nutrition and Functional Foods, Laval University	Diet (HEI-C)	HOMA-IR	↓
		Overweight	Beta-cell response	↑
			Triglycerides	n.s.
			HDL	n.s.
Kelstrup 2016 ⁷¹	N/A	Gene Expression (Adipose Tissue: PPARGC1A)	HOMA-IR	n.s.
		DNA Methylation + BMI	HOMA-IR	↑

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; HEI - healthy eating index; HDL – high density lipoprotein; HOMA-IR – homeostatic model assessment of insulin resistance; HbA1c – hemoglobin A1c; MetS – metabolic syndrome; n.s. - not significant; T2D – type 2 diabetes.

TABLE 8. Randomized control trials evaluating prognostic factors associated with cardiometabolic outcomes among offspring exposed to GDM *in utero* ($n=7$).

Author Year	Trial Name	Intervention and/or Exposure	Offspring Outcome	Association
Landon 2015 ¹¹⁰	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Treatment (dietary intervention, self-monitoring of glucose, and insulin therapy) vs. standard of care	Blood pressure	n.s.
			Lipids	n.s.
			HOMA-IR	n.s.
			Offspring sex (male vs. female)	↓
Grotenfelt 2020 ¹¹¹	Finnish Gestational Diabetes Prevention Study (RADIEL)	Lifestyle intervention (counseling of exercise and diet)	Metabolic risk profile	↑
Keely 2008 ¹¹²	RCT at the Ottawa Hospital (General and Civic campuses) and the Children's Hospital of Eastern Ontario, in Ottawa, Canada	Treatment (regular check-ups + dietary counseling) vs. Routine Care	Lipids	↑
			HOMA-IR	↑
			Glucose (fasting and 2 hour)	n.s.
Malcolm 2006 ¹¹³	RCT at the Ottawa Hospital (General and Civic campuses) and the Children's Hospital of Eastern Ontario, in Ottawa,	Treatment (regular check-ups and were given dietary counseling) vs.	Fasting glucose	n.s.

	Canada	Routine Care		
Wroblewska-Seniuk 2009 ⁹¹	Children born in Clinical Hospital of Obstetrics and Gynecology in Poznan, Poland	Treatment (diet vs. insulin)	Glucose	n.s.
			Insulin	n.s.
			HOMA-IR	n.s.
			HbA1c	n.s.
Egeland 2010 ⁶¹	N/A	Treatment (diet vs. insulin)	Insulin	↓
			Glucose	↓
			Fasting glucose	n.s.
			Lipids	n.s.
			HOMA-IR	n.s.
Battin 2015 ¹¹⁴	MiG Trial	Treatment (diet vs. insulin)	Blood pressure	n.s.

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; HOMA-IR – homeostatic model assessment of insulin resistance; HbA1c – hemoglobin A1c; : n.s. - not significant; T2D – type 2 diabetes.

FIGURE 1. Systematic review screening and attrition diagram.

